Clinical Trials

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05963074 2026-03-13

TAILOR

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02629809 2026-03-06

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

81 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03506373 2026-03-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Waldenstrom Macroglobulinemia

NCT04802590 2026-03-04

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

194 enrolled

Lymphoma, Mantle-Cell

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Phase 2 Terminated

5 enrolled 11 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01880567 2026-02-19

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

113 enrolled

Lymphoma, Mantle-Cell

NCT02756897 2026-02-19

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

234 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03198026 2026-02-19

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

30 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT05998642 2026-02-12

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

30 enrolled

Lymphoma, Non-Hodgkin

NCT03710772 2026-02-11

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT02649387 2026-02-10

MERIT

35 enrolled 7 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03282396 2026-02-06

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

20 enrolled

Lymphoma, Mantle-Cell

NCT03513562 2026-02-06

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

28 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

15 enrolled 9 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03697512 2026-01-15

MALIBU

175 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT02518555 2026-01-07

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

42 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03708003 2025-12-30

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Phase 2 Terminated

30 enrolled

Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06271616 2025-12-26

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

40 enrolled

Bronchiolitis Obliterans Syndrome

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

112 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT03620903 2025-12-05

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

53 enrolled

Waldenstrom Macroglobulinemia

NCT02666898 2025-11-26

ICLL07GAI

135 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT03734198 2025-11-26

IDA53

29 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

79 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02427620 2025-11-21

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

90 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02251548 2025-10-24

iFCR

85 enrolled 17 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06520098 2025-10-14

Benefit VA

100 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01849263 2025-09-10

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

41 enrolled 12 charts

Lymphoma, Follicular

NCT02581930 2025-09-08

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

18 enrolled 10 charts

Dermatologic

Melanoma

NCT03207555 2025-09-02

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

23 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04273139 2025-07-30

Ibrutinib + Venetoclax in Untreated WM

45 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT01589302 2025-07-25

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

154 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT04477486 2025-07-09

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

13 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT04062448 2025-05-25

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

16 enrolled 14 charts

Waldenstrom Macroglobulinemia

NCT04685915 2025-05-22

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Phase 2 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04450173 2025-04-24

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

40 enrolled

Lymphoma, Follicular

NCT03646461 2025-04-06

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

5 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04263480 2025-04-04

CZAR-1

99 enrolled

Waldenstrom Macroglobulinemia, Neoplasms

NCT02824029 2025-02-17

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

28 enrolled 11 charts

Hodgkin Disease

NCT02388048 2025-01-29

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

19 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02643667 2025-01-08

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

27 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT02207062 2025-01-07

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

20 enrolled 15 charts

Lymphoma, Non-Hodgkin

NCT02910583 2024-12-20

Captivate

323 enrolled 33 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04234061 2024-11-07

TARMAC

20 enrolled

Lymphoma, B-Cell

NCT02692248 2024-10-10

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

64 enrolled 17 charts

Lymphoma, Large B-Cell, Diffuse

NCT02532257 2024-09-24

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

48 enrolled 15 charts